Clinical markers of disease progression in the prodromal to overt alpha-synucleinopathy continuum - PubMed
an hour ago
- #Sleep Disorders
- #Neurodegeneration
- #Disease Progression
- Study focuses on disease progression markers for alpha-synucleinopathies, using a Disease Course Map (DCM) model in iRBD patients.
- Three individual clinical markers were identified: time shift (τ), acceleration factor (α), and intermarker spacing (δ), reflecting progression speed and trajectory.
- These markers can distinguish converters from non-converters with 73% accuracy and correlate with neurodegeneration biomarkers like dopaminergic impairment and cortical theta band synchronization.
- Motor scores progress 35% faster than cognitive scores; converter patients show earlier and faster progression, with motor worsening often preceding cognitive decline.
- Clinical markers are proposed as potential efficacy endpoints for disease-modifying clinical trials.